Vitamin D Deficiency Should Be Corrected in Thyroid Eye Disease Patients, But Supplementation Beyond Repletion Is Not Indicated for Treatment
Based on current evidence, vitamin D deficiency should be identified and corrected in patients with thyroid eye disease (TED), as deficiency is an independent risk factor for developing TED, but there is no evidence supporting high-dose vitamin D supplementation as a disease-modifying treatment.
Vitamin D as a Risk Factor for TED
Serum vitamin D deficiency is recognized as an independent risk factor for developing thyroid eye disease 1. Research demonstrates that TED patients have significantly lower serum 25(OH)D levels compared to Graves disease patients without eye involvement (24.8 ± 13.2 ng/ml vs. 29.4 ± 13.3 ng/ml; p = 0.006), and this association persists even after controlling for smoking and radioactive iodine treatment 2. The 2020 Adult Strabismus guideline specifically identifies "serum vitamin D deficiency" as an independent risk factor for developing TED 1.
In clinical practice, vitamin D deficiency is highly prevalent in TED populations—one study found 73% of TED patients had baseline 25(OH)D deficiency (<20 ng/ml) 3, while another Texas-based study found 20% with deficiency and 31% with insufficiency 4.
Screening and Repletion Recommendations
Check serum 25(OH)D levels in all patients with TED or Graves disease at risk for TED. If deficiency (<20 ng/ml) or insufficiency (20-30 ng/ml) is identified, treat according to standard vitamin D deficiency protocols 5:
- For adults with vitamin D deficiency: 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, or 6,000 IU daily, to achieve 25(OH)D above 30 ng/ml, followed by maintenance of 1,500-2,000 IU daily 5
- Monitor 25(OH)D levels to confirm adequate repletion
No Role for High-Dose Supplementation as TED Treatment
Despite the association between vitamin D deficiency and TED risk, there is no evidence that vitamin D supplementation improves TED outcomes or modifies disease activity. The DAGMAR trial—a high-quality, multicenter, double-blind RCT—found that vitamin D supplementation (70 mcg/2,800 IU daily) did not reduce failure to achieve remission in Graves disease patients (relative risk 1.30,95% CI 0.95-1.78) 6. This trial specifically concluded that "supplementation with high-dose vitamin D cannot be recommended for GD" 6.
A systematic review examining vitamin D across multiple ocular diseases found limited evidence for TED specifically, with only weak associations reported 7.
Potential Predictive Value During Treatment
One retrospective study suggests that changes in vitamin D levels during intravenous glucocorticoid (IVGC) therapy may predict treatment response 3. Responders to IVGC showed significantly greater increases in 25(OH)D (Δ25(OH)D) compared to non-responders, with an optimal cutoff of +2.7 ng/ml predicting response (AUC = 0.732). However, this was a single retrospective study with standardized vitamin D/calcium supplementation given to all patients, so it cannot determine whether vitamin D supplementation itself improves outcomes or merely serves as a biomarker.
Clinical Algorithm
- At TED diagnosis: Measure serum 25(OH)D
- If 25(OH)D <20 ng/ml: Treat with 50,000 IU weekly × 8 weeks or 6,000 IU daily
- If 25(OH)D 20-30 ng/ml: Consider repletion with lower doses (2,000-4,000 IU daily)
- Target level: Achieve 25(OH)D ≥30 ng/ml
- Maintenance: 1,500-2,000 IU daily once replete
- Do NOT use high-dose vitamin D (>2,000-4,000 IU daily) as disease-modifying therapy
Important Caveats
- The association between vitamin D deficiency and TED does not prove causation—vitamin D deficiency may be a marker of autoimmune disease severity rather than a modifiable risk factor
- No clinical trials have demonstrated that correcting vitamin D deficiency prevents TED development or improves TED outcomes
- Routine vitamin D supplementation beyond standard repletion doses is not supported by evidence and should not be recommended as TED-specific therapy 8
- The 2024 Endocrine Society guideline on vitamin D for disease prevention does not include TED as an indication for empiric supplementation 8
In summary: Correct vitamin D deficiency when present using standard repletion protocols, but do not prescribe vitamin D as a treatment for thyroid eye disease itself.